TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21486113

Group type: EXPERIMENTAL
Intervention: Long-term anticoagulation therapy with warfarin (OAC group)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (no anticoagulant or antiaggregant drugs)
Number of subjects: 31
Study: 18647510

Group type: EXPERIMENTAL
Intervention: Cavities prepared with Er, Cr:YSGG laser (power settings varying for enamel=2.5 W and 3 W and dentine=1.0 W and 1.5 W) and restored with resin-modified glass ionomer cement (RMGIC) (Vitremer)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Cavities prepared with high-speed drill (HD) and restored with conventional glass ionomer cement (CGIC) (Ketac Molar Easy Mix)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Cavities prepared with Er, Cr:YSGG laser and restored with CGIC
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Cavities prepared with high-speed drill and restored with RMGIC
Number of subjects: 100
Study: 17138219

Group type: EXPERIMENTAL
Intervention: Sentinel-lymph-node biopsy (SLNB) followed by ALND only if the SLN was involved (SLN group)
Number of subjects: 516

Group type: COMPARATOR
Intervention: Sentinel-lymph-node biopsy (SLNB) and total axillary-lymph-node dissection (ALND group)
Number of subjects: 516

Group type: COMPARATOR
Intervention: Overall survival in the ALND group
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: Overall survival in the SLN group
Number of subjects: 516
Study: 12753370

Group type: EXPERIMENTAL
Intervention: Subgingival irrigation with 10% PVP-iodine together with scaling and root planing
Number of subjects: 16

Group type: COMPARATOR
Intervention: Scaling and root planing alone
Number of subjects: 16

Group type: COMPARATOR
Intervention: Subgingival irrigation with 10% PVP-iodine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Subgingival irrigation with sterile saline
Number of subjects: 16
Study: 11789221

Group type: EXPERIMENTAL
Intervention: Composite Salviae Dropping Pill (CSDP), 10 pills three times a day for 4 weeks
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (aspirin and other conservative agents only)
Number of subjects: 42
Study: 9095007

Group type: COMPARATOR
Intervention: Albuterol (2.5 mg) every 60 minutes for two doses, interspersed with saline aerosols every 20 minutes
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Albuterol (2.5 mg) every 20 minutes for 2 hours
Number of subjects: 86
Study: 8459640

Group type: EXPERIMENTAL
Intervention: Tegafur plus mitomycin C
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: UFT (uracil and tegafur in a 4:1 molar ratio) plus mitomycin C
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Primary gastric lesion responded to chemotherapy
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Primary gastric lesion did not respond to chemotherapy
Number of subjects: 169
Study: 28880576

Group type: EXPERIMENTAL
Intervention: Internet-based motivational intervention (IMI) supported by pedometers
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Internet-based motivational intervention (IMI) alone
Number of subjects: 76

Group type: COMPARATOR
Intervention: Non-intervention
Number of subjects: 76
Study: 28303753

Group type: EXPERIMENTAL
Intervention: FTC/TAF
Number of subjects: 663

Group type: COMPARATOR
Intervention: FTC/TAF (boosted PI)
Number of subjects: 663

Group type: COMPARATOR
Intervention: FTC/TDF (boosted PI)
Number of subjects: 663

Group type: COMPARATOR
Intervention: FTC/TAF (unboosted third agent)
Number of subjects: 663

Group type: COMPARATOR
Intervention: FTC/TDF (unboosted third agent)
Number of subjects: 663
Study: 25085943

Group type: EXPERIMENTAL
Intervention: SiPAP (bi-level nasal CPAP)
Number of subjects: 20

Group type: COMPARATOR
Intervention: nCPAP (conventional nasal CPAP)
Number of subjects: 20
Study: 22562974

Group type: EXPERIMENTAL
Intervention: MR prednisone 5 mg once daily in the evening plus DMARD
Number of subjects: 350

Group type: COMPARATOR
Intervention: Placebo plus DMARD
Number of subjects: 350
Study: 21903909

Group type: EXPERIMENTAL
Intervention: Dual-energy CT (DECT) with tube voltages 80 and Sn140 kVp
Number of subjects: 64

Group type: COMPARATOR
Intervention: Standard single-energy CT (SECT) at 120 kVp
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Dual-energy CT (DECT)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Standard single-energy CT (SECT)
Number of subjects: 64
Study: 18422837

Group type: EXPERIMENTAL
Intervention: TIMP1, PIIINP, HA (adjusted for age)
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Various serum markers (TIMP1, tenascin, collagen VI, PIIINP, MMP2, laminin, HA)
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Markers assessed every 3 months
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Receiver operating curves (ROC) analysis
Number of subjects: 247
Study: 16972709

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 12559133

Group type: EXPERIMENTAL
Intervention: Shallow endotracheal suctioning (ETS)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Deep endotracheal suctioning (ETS)
Number of subjects: 27
Study: 10792143

Group type: EXPERIMENTAL
Intervention: Cuff inflated
Number of subjects: 149

Group type: COMPARATOR
Intervention: Cuff deflated
Number of subjects: 149
Study: 9358137

Group type: EXPERIMENTAL
Intervention: 100 microg of budesonide plus 12 microg of formoterol
Number of subjects: 852

Group type: EXPERIMENTAL
Intervention: 400 microg of budesonide plus 12 microg of formoterol
Number of subjects: 852

Group type: COMPARATOR
Intervention: 100 microg of budesonide plus placebo
Number of subjects: 852

Group type: COMPARATOR
Intervention: 400 microg of budesonide plus placebo
Number of subjects: 852
Study: 8179543

Group type: COMPARATOR
Intervention: Surgicraft Copeland clip fetal scalp electrode (52 patients)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Meditrace spiral single helix scalp electrode (54 patients)
Number of subjects: 106
Study: 3516752

Group type: EXPERIMENTAL
Intervention: Dipyrone 500 mg
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Aspirin 500 mg
Number of subjects: 254

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 254
Study: 31331006

Group type: EXPERIMENTAL
Intervention: Higher levels of any of the ten individual fatty acids (genetic predisposition)
Number of subjects: 588190
Study: 29923294

Group type: EXPERIMENTAL
Intervention: BioChaperone Lispro (BCLIS)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Insulin lispro (LIS)
Number of subjects: 35
Study: 26708298

Group type: EXPERIMENTAL
Intervention: Community-based health insurance (CBHI) schemes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 24731301

Group type: EXPERIMENTAL
Intervention: Surgery (anterior discectomy or posterior foraminotomy)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Prolonged conservative care with surgery if needed
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 400

Group type: COMPARATOR
Intervention: Conservative care
Number of subjects: 400
Study: 23038415

Group type: EXPERIMENTAL
Intervention: 20 mL of 0.25% levobupivacaine with 5 μg/mL epinephrine
Number of subjects: 11

Group type: COMPARATOR
Intervention: 20 mL of 0.25% levobupivacaine without epinephrine
Number of subjects: 11
Study: 20400097

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 41

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 41
Study: 17700386

Group type: EXPERIMENTAL
Intervention: Phone result disclosure
Number of subjects: 111

Group type: COMPARATOR
Intervention: In-person result disclosure
Number of subjects: 111
Study: 16005438

Group type: EXPERIMENTAL
Intervention: Metyrapone (cortisol synthesis inhibitor)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 14564242

Group type: COMPARATOR
Intervention: Vecuronium (1.3 mg/kg)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Rocuronium (0.6 mg/kg)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Atracurium (0.5 mg/kg)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Cisatracurium (0.15 mg/kg)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Vecuronium (0.1 mg/kg)
Number of subjects: 126
Study: 10503666

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (HA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exogenous HA
Number of subjects: 0
Study: 8661828

Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy
Number of subjects: 64

Group type: COMPARATOR
Intervention: Open appendectomy
Number of subjects: 64
Study: 1832944

Group type: COMPARATOR
Intervention: TAM (20 mg b.i.d.)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: TAM-MPA (TAM 20 mg b.i.d. for 7 days, then TAM plus 500 mg MPA for 7 days)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: TAM-MPA
Number of subjects: 20

Group type: COMPARATOR
Intervention: TAM
Number of subjects: 20
Study: 6125199

Group type: EXPERIMENTAL
Intervention: Cimetidine (1 g per day)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Atenolol (100 mg)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Metoprolol (100 mg)
Number of subjects: 2
Study: 31950378

Group type: COMPARATOR
Intervention: Control group (Group 1)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: FiberSite post luting with Clearfil DC Core Plus (Group 2)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: RelyX Fiber post luting and core build up with Clearfil DC Core Plus (Group 3)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: RelyX Fiber post luting with Clearfil DC Core Plus and core build up with Filtek Bulk Fill Posterior (Group 4)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Specimens that received CAD/CAM crowns after procedures in Groups 2, 3, and 4 (Groups 5, 6, and 7)
Number of subjects: 140
Study: 31408150

Group type: EXPERIMENTAL
Intervention: Home pregnancy tests provided to CHWs for free distribution
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no home pregnancy tests)
Number of subjects: 0
Study: 26580123

Group type: EXPERIMENTAL
Intervention: 20% mannitol
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 3% hypertonic saline (HS)
Number of subjects: 40
Study: 27283093

Group type: EXPERIMENTAL
Intervention: Zero-priced voucher for circumcision
Number of subjects: 1649

Group type: COMPARATOR
Intervention: Positive-priced voucher for circumcision
Number of subjects: 1649
Study: 24129336

Group type: EXPERIMENTAL
Intervention: Vibration response imaging (VRI)
Number of subjects: 23
Study: 22329774

Group type: EXPERIMENTAL
Intervention: Intranasal triamcinolone acetonide
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 19021097

Group type: EXPERIMENTAL
Intervention: Packed red blood cell transfusion during feeding
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Feeding in anemic infants > 1250 g
Number of subjects: 22

Group type: COMPARATOR
Intervention: Transfusion without feeding
Number of subjects: 22
Study: 17936446

Group type: EXPERIMENTAL
Intervention: Live-attenuated influenza vaccine, trivalent
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15767500

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy
Number of subjects: 3709

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3709
Study: 11985880

Group type: EXPERIMENTAL
Intervention: Creatine (8 g/day for 5 days)
Number of subjects: 0
Study: 10397695

Group type: EXPERIMENTAL
Intervention: Recombinant hirudin (r‐hirudin) 0.35 mg/kg
Number of subjects: 17

Group type: COMPARATOR
Intervention: Physiological saline (control)
Number of subjects: 17
Study: 8749149

Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg daily
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Loratadine 40 mg daily
Number of subjects: 8

Group type: COMPARATOR
Intervention: Clemastine 2 mg twice daily
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 2202458

Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 97
Study: 6282302

Group type: COMPARATOR
Intervention: Medium-fibre coarse-bran bread diet (22 g NDF/d)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: High-fibre coarse-bran bread diet (35 g NDF/d)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Medium-fibre fine-bran bread diet (22 g NDF/d)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Wholemeal bread diet (22 g NDF/d)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Coarse-bran bread diet (22 g NDF/d)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Low-fibre white bread diet (9 g NDF/d)
Number of subjects: 12
Study: 31418933

Group type: EXPERIMENTAL
Intervention: Cornus mas extract (CME) 300 mg, 3 capsules per day for 8 weeks
Number of subjects: 84

Group type: COMPARATOR
Intervention: Starch powder, 3 capsules per day for 8 weeks
Number of subjects: 84
Study: 28609534

Group type: EXPERIMENTAL
Intervention: Ferrous sulfate (3 mg/kg of elemental iron once daily for 12 weeks)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Iron polysaccharide complex (3 mg/kg of elemental iron once daily for 12 weeks)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Ferrous sulfate
Number of subjects: 80

Group type: COMPARATOR
Intervention: Iron polysaccharide complex
Number of subjects: 80
Study: 26360834

Group type: EXPERIMENTAL
Intervention: Acamprosate calcium tablets (multiple dosing)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Acamprosate calcium tablets (single dosing under fasting conditions)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Acamprosate calcium tablets (single dosing under fed conditions)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Acamprosate calcium tablets (bioequivalence evaluation)
Number of subjects: 36
Study: 23642776

Group type: EXPERIMENTAL
Intervention: EVOO (50ml daily)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (maintained dietary habits)
Number of subjects: 62
Study: 21276616

Group type: EXPERIMENTAL
Intervention: Dual-Focus (DF) lenses
Number of subjects: 40

Group type: COMPARATOR
Intervention: Single Vision Distance (SVD) lenses
Number of subjects: 40
Study: 19995648

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen (CEE) and medroxyprogesterone acetate (MPA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 17785705

Group type: EXPERIMENTAL
Intervention: Denosumab (30, 120, or 180 mg subcutaneously every 4 weeks; 60 or 180 mg every 12 weeks)
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 255

Group type: COMPARATOR
Intervention: IV Bisphosphonates (IV BP)
Number of subjects: 255
Study: 14988895

Group type: EXPERIMENTAL
Intervention: gamma radiation treatment (gamma‐RT)
Number of subjects: 130

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 130
Study: 10674758

Group type: EXPERIMENTAL
Intervention: Mild closed head injury (GCS 13-15)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Extensive penetrating head injury (GCS 4-6)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Blast injuries without direct head trauma
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: All groups (mild, extensive, blast)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: GCS 13-15 and blast injury groups
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Extensive head injury (GCS 4-6)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: GCS 4-6 patients
Number of subjects: 31
Study: 9056731

Group type: EXPERIMENTAL
Intervention: Sagodana based ORS
Number of subjects: 112

Group type: COMPARATOR
Intervention: Rice based ORS
Number of subjects: 112
Study: 1406416

Group type: EXPERIMENTAL
Intervention: Pravastatin 20 mg/day
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg/day
Number of subjects: 61

Group type: COMPARATOR
Intervention: Cholestyramine 16 g/day
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Pravastatin (long-term treatment)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Resin (long-term treatment)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Pravastatin (12 weeks monotherapy)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Resin (12 weeks monotherapy)
Number of subjects: 61
Study: 3970333

Group type: EXPERIMENTAL
Intervention: Oral diazepam 0.25 mg/kg
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Oral diazepam 0.5 mg/kg
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control values (not specified)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Both doses of diazepam (0.25 mg/kg and 0.5 mg/kg)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Higher premedication dose (0.5 mg/kg)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Plasma diazepam levels
Number of subjects: 101
Study: 31748169

Group type: EXPERIMENTAL
Intervention: Intensive multifactorial treatment
Number of subjects: 3031

Group type: COMPARATOR
Intervention: Routine diabetes care
Number of subjects: 3031
Study: 29474292

Group type: EXPERIMENTAL
Intervention: Pessary removal daily
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Pessary removal at least weekly
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Pessary removal less often than once weekly
Number of subjects: 137
Study: 27941661

Group type: EXPERIMENTAL
Intervention: Phosphorus supplementation (500 mg)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 24398943

Group type: EXPERIMENTAL
Intervention: Alcohol (BrAC up to 0.6 g/kg for 15 minutes followed by 100 minutes exposure)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 22520742

Group type: EXPERIMENTAL
Intervention: French version of the QUAL‐E questionnaire
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: French version of the MVQOLI questionnaire
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: Randomized clinical trial component
Number of subjects: 372
Study: 20831133

Group type: EXPERIMENTAL
Intervention: Formocresol (PDC)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Calcium hydroxide (CDC)
Number of subjects: 120
Study: 19069799

Group type: EXPERIMENTAL
Intervention: Combined treatment including physical factors (a constant magnetic field and negatively polarized phytoaeroions), soft‐tissue manual therapy, and dosed physical exercises.
Number of subjects: 0
Study: 15736746

Group type: EXPERIMENTAL
Intervention: Ferrous sulphate
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 12517681

Group type: EXPERIMENTAL
Intervention: Drug withdrawal program
Number of subjects: 25826
Study: 10799721

Group type: EXPERIMENTAL
Intervention: 7-day continuous accelerated irradiation (CAIR)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional treatment (5 days per week)
Number of subjects: 100
Study: 8641735

Group type: EXPERIMENTAL
Intervention: Black hypertensive subjects
Number of subjects: 77

Group type: COMPARATOR
Intervention: White hypertensive subjects
Number of subjects: 77
Study: 1563806

Group type: EXPERIMENTAL
Intervention: Barbiturates (high-dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Barbiturates (low-dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (without barbiturates)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Barbiturates (all patients)
Number of subjects: 0
Study: 371650

Group type: EXPERIMENTAL
Intervention: i.v. injection of oxytocin 10 u
Number of subjects: 88

Group type: COMPARATOR
Intervention: ergometrine 0.5 mg
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: continuous infusion of dilute oxytocin
Number of subjects: 88

Group type: COMPARATOR
Intervention: i.v. ergometrine
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: oxytocin
Number of subjects: 88
Study: 30939472

Group type: EXPERIMENTAL
Intervention: Urinary IL‐18
Number of subjects: 2377

Group type: EXPERIMENTAL
Intervention: YKL‐40
Number of subjects: 2377

Group type: COMPARATOR
Intervention: CVD events
Number of subjects: 2377

Group type: COMPARATOR
Intervention: All-cause mortality
Number of subjects: 2377
Study: 27943617

Group type: EXPERIMENTAL
Intervention: Postoperative ileus (POI) group
Number of subjects: 108

Group type: COMPARATOR
Intervention: No postoperative ileus (POI) group
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Patients with anastomotic leakage (AL)
Number of subjects: 108
Study: 25576433

Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Number of subjects: 351

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 351
Study: 24313178

Group type: EXPERIMENTAL
Intervention: Double distant space technique (DDS)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Single space technique (SST)
Number of subjects: 156
Study: 21226679

Group type: EXPERIMENTAL
Intervention: Food supplement (5 mg melatonin, 225 mg magnesium, and 11.25 mg zinc, mixed with 100 g of pear pulp)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Food supplement (5 mg melatonin, magnesium, and zinc)
Number of subjects: 43
Study: 19392928

Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF)
Number of subjects: 0
Study: 17383527

Group type: EXPERIMENTAL
Intervention: Filgrastim (5 mug/kg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 16620649

Group type: EXPERIMENTAL
Intervention: Silver nanoparticle dressing (Group A)
Number of subjects: 191

Group type: COMPARATOR
Intervention: 1% silver sulfadiazine cream (Group B)
Number of subjects: 191

Group type: COMPARATOR
Intervention: Vaseline gauze (Group C)
Number of subjects: 191
Study: 12732773

Group type: EXPERIMENTAL
Intervention: Mesna solution
Number of subjects: 44

Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 44
Study: 9862770

Group type: EXPERIMENTAL
Intervention: Cocaine (10 mg/70 kg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cocaine (20 mg/70 kg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cocaine (40 mg/70 kg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nicotine (0.75 mg/70 kg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nicotine (1.5 mg/70 kg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nicotine (3.0 mg/70 kg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 7558527

Group type: EXPERIMENTAL
Intervention: Treadmill low walking (LW)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Cycle ergometry (BK)
Number of subjects: 8